Novel drug delivery systems based on the regulation of alveolar functions for treatment of lung diseases

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K19165
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Applied pharmacology
• Research Institution: Hokkaido Pharmaceutical University School of Pharmacy
• Principal Investigator: Togami Kohei 北海道薬科大学, 薬学部, 講師 (20582357)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肺線維症 / 肺がん / 細胞外マトリックス / 微粒子製剤 / イメージング / siRNA / 抗線維化薬

Outline of Final Research Achievements

Lung cancer and pulmonary fibrosis is a progressive and lethal lung disease characterized by the accumulation of extracellular matrix, loss of pulmonary function, and change in lung structure. In this study, the delivery efficiency after intrapulmonary administration of nanoparticles to mice with metastatic lung tumor and bleomycin-induced pulmonary fibrosis. The anti-tumor siRNA-containing nanoparticles for intrapulmonary administration had tumor-cell specificity and delivery efficiency effectively silenced the oncogenes in the lung metastasis. Aerosolized PEGylated liposomes were efficiently delivered to fibrotic legions. This study suggests that aerosol-based novel nanoparticles are a new therapeutic strategy.

Free Research Field

製剤学